Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Drug cycling with collateral sensitivity

Published byLorraine Norton Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Drug cycling with collateral sensitivity"— Presentation transcript:

1 Figure 3 Drug cycling with collateral sensitivity
Figure 3 | Drug cycling with collateral sensitivity. Drug cycling with collateral sensitivity uses rational drug-pairing to eradicate treatment-resistant cancer cells. Tumours that have become resistant to a drug should be rationally treated with a new combination of drugs. The application of consecutive cycles of complementary anticancer drugs could, in principle, be more effective than conventional single-agent or drug-pairing protocols that lack the benefits of collateral sensitivity. The cyclical application of drug partners working through collateral sensitivity could maximize cytotoxic effects while, at the same time, minimizing toxicities in patients. Roubaud, G. et al. (2016) Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 3 Drug cycling with collateral sensitivity"

Similar presentations

Optimization of personalized therapies for anticancer treatment Alexei Vazquez The Cancer Institute of New Jersey.

Optimization of personalized therapies for anticancer treatment Alexei Vazquez The Cancer Institute of New Jersey.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Volume 1, Issue 5, Pages (November 2007)

Volume 1, Issue 5, Pages (November 2007)
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google